A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Silence Therapeutics

Status and phase: Completed; Phase 1

Conditions: Non-transfusion-dependent Thalassemia; Low Risk Myelodysplastic Syndrome; Very-Low Risk Myelodysplastic Syndrome

Treatments: Drug: Placebo; Drug: SLN124

Study type: Interventional

Funder types: Industry

Identifiers

NCT04718844

SLN124-002

Details and patient eligibility

About

This study will investigate the safety and tolerability of SLN124 in patients with Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome (MDS) after single ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts of 56 patients with Thalassaemia and up to 7 cohorts of 56 patients with MDS will be enrolled. Each subject will receive single or multiple doses of SLN124 or placebo given by subcutaneous (s.c) injection.

Enrollment: 44 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Adult with alpha- or beta-thalassaemia or compound heterozygous haemoglobin E/beta-thalassaemia or adult with very low- or low-risk MDS according to the 2016 revision to the World Health Organisation classification.
• All subjects must agree to adhere to appropriate contraception requirements.
• Subjects must provide written informed consent and be able to comply with all study requirements.
• Body mass index ≥18 kg/m2 and ≤35 kg/m2 at screening.
• At least one of: a) Mean ferritin >250 μg/L based on a minimum of 2 measurements ≥1 week apart within 20 days before the planned dosing day, in the absence of active significant infection; b) Mean TSAT >40% measured on a minimum of 2 occasions ≥1 week apart within 20 days before the planned dosing day; c) Liver iron >3 mg Fe/g dry weight, measured according to local procedures.
• Mean baseline haemoglobin concentration ≥5 g/dL and ≤11 g/dL, based on a minimum of 2 measurements ≥1 week apart, within 20 days before the planned dosing day.

Exclusion criteria

• Adult with haemoglobin S/alpha-thalassaemia or haemoglobin S/beta-thalassaemia or adult with secondary MDS, i.e., MDS that is known to have arisen because of chemical injury or treatment with chemotherapy and/or radiation for another disease.
• History of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc, or intolerance to s.c. injections.
• Known infection with HIV, or active infectious hepatitis A, B, or C virus.
• Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrolment in the study or could interfere with the subject's participation in, or completion of the study.
• History or clinical evidence of alcohol or illegal drug misuse within 2 years before screening.
• Currently using ESA, or plan to use ESA at any point during the study.
• Require daily treatment with 1 or more non-steroidal anti-inflammatory drugs during the study period. Paracetamol will be permitted for use as an antipyretic and/or analgesic.
• Treatment, or change in treatment with prohibited medications as specified in the protocol
• Treatment with ICT where the subject has not been on a stable dose for at least 8 weeks before screening or it is planned to initiate ICT therapy during the study.
• Clinically significant cardiac disease
• Clinically significant pulmonary disease

For subjects with thalassaemia:

• Treatment, or change in treatment with prohibited medications as specified in the protocol
• currently and anticipated to receiving more than 5 units of RBCs during the 24 weeks to 6 weeks period before first dose of study drug.

For subjects with very low / low-risk MDS:

• Previous allogeneic or autologous stem cell transplantation.
• Currently or planned to receive treatment with a corticosteroid for MDS within 8 weeks before screening.
• Currently or planned to receive treatment with haematopoietic growth factors (e.g., eltrombopag, romiplostim) within 8 weeks before screening.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

44 participants in 18 patient groups, including a placebo group

1.0mg/kg - Thalassaemia

Experimental group

Treatment:

Drug: SLN124

3.0mg/kg - Thalassaemia

Experimental group

Treatment:

Drug: SLN124

6.0mg/kg - Thalassaemia

Experimental group

Treatment:

Drug: SLN124

Placebo - Thalassaemia

Placebo Comparator group

Treatment:

Drug: Placebo

Xmg/kg - Thalassaemia

Experimental group

Treatment:

Drug: SLN124

1.0mg/kg - Myelodysplastic Syndrome

Experimental group

Treatment:

Drug: SLN124

3.0mg/kg - Myelodysplastic Syndrome

Experimental group

Treatment:

Drug: SLN124

10.0mg/kg - Myelodysplastic Syndrome

Experimental group

Treatment:

Drug: SLN124

Xmg/kg - Myelodysplastic Syndrome

Experimental group

Treatment:

Drug: SLN124

3.0mg/kg - Thalassaemia multi dose

Experimental group

Treatment:

Drug: SLN124

10.0mg/kg - Thalassaemia multi dose

Experimental group

Treatment:

Drug: SLN124

Xmg/kg - Thalassaemia multi dose

Experimental group

Treatment:

Drug: SLN124

3.0mg/kg - Myelodysplastic Syndrome multi dose

Experimental group

Treatment:

Drug: SLN124

10.0mg/kg - Myelodysplastic Syndrome multi dose

Experimental group

Treatment:

Drug: SLN124

Xmg/kg - Myelodysplastic Syndrome multi dose

Experimental group

Treatment:

Drug: SLN124

Placebo - Thalassaemia multi dose

Placebo Comparator group

Treatment:

Drug: Placebo

Placebo - Myelodysplastic Syndrome

Placebo Comparator group

Treatment:

Drug: Placebo

Placebo - Myelodysplastic Syndrome multi dose

Placebo Comparator group

Treatment:

Drug: Placebo